drugset / Trial / NCT02792062

A Food Effect Study of TAK-385 Final Formulation

NCT02792062

Phase 1 Completed 12 enrolled Takeda
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate food effects on the pharmacokinetics of a single oral dose of TAK-385 in Japanese premenopausal healthy adult women.

Timeline

Start
2016-07-04
Primary completion
2016-08-31
Completion
2016-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Relugolix Small molecule 40 mg Oral

Indications

No indication recorded.